Gliadin p31-43 is used in the study of celiac disease; it induces innate immune responses in the gut and disrupts endocytic trafficking; it activates the MyD88/TLR7 complex and downstream MAPK signaling pathways (including ERK, JNK, and p38); it increases NF-κB phosphorylation and MxA protein levels; it upregulates IFN-α7 and IFN-α17 mRNA expression; it interferes with HRS localization to early endosomes, delaying endocytic vesicle maturation; it forms structured oligomers and aggregates that activate the ASC inflammasome complex; it triggers NLRP3 inflammasome activation and caspase-1-dependent IL-1β production in the small intestinal mucosa.